Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

Roivant has its own TYK2/JAK1 inhibitor in development in the form of brepocitinib, which the biopharma licensed from Pfizer ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...

Please enter your username and password below, if you are not yet a member of BioTechniques remember you can register for ...

A Massachusetts-based wound care and sports medicine company announced plans for its brand-new biomanufacturing facility ...

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as ...

Hyderabad-based Bharat Biotech International Ltd. has claimed that its oral cholera vaccine (OCV) under development, Hillchol ...

Walter Isaacson, ‘Elon Musk’ author, Perella Weinberg Partners advisory partner and Tulane professor, joins 'Squawk Box' to ...

FBT ETF launched 19 years ago and has delivered exceptional returns compared to the broader Health Care sector. Read why FBT ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Bharat Biotech’s oral cholera vaccine, Hillchol, aims to ease a critical global shortfall, with the world currently lacking ...